Tego Science Inc

Tego Science Inc maintains a strong liquidity position with cash and equivalents of KRW 12.64 billion, which is 45.7% of total assets, and a current ratio of 15.58, indicating robust short-term financial health. The company's price-to-book ratio of 2.09 and price-to-tangible-book ratio of 2.09 suggest a moderate valuation relative to its equity base. However, the company's negative operating income of KRW -4.42 billion and net income of KRW -7.01 billion indicate significant operational challenges. The company's return on equity of -13.88% and return on assets of -8.97% are well below the industry norms for pharmaceuticals, which typically exhibit positive returns due to high-margin product lines. Gross profit of KRW 4.04 billion on revenue of KRW 5.94 billion yields a gross margin of 68%, which is strong but insufficient to offset the company's high operating expenses. Tego Science Inc's revenue is concentrated in its core biopharmaceuticals and CDMO services, with no disclosed geographic diversification in the input data. The company's property rental business is a minor contributor to revenue, and no material geographic exposure is reported. The company's revenue of KRW 5.94 billion in the latest period reflects a challenging growth trajectory, with no disclosed prior-year revenue to assess year-over-year performance. The negative operating cash flow of KRW -3.07 billion and free cash flow of KRW -6.97 billion suggest ongoing cash burn, which could pressure future growth unless operational efficiency improves. The risk assessment highlights medium liquidity risk due to negative net cash after subtracting total debt, and low dilution risk with no near-term pressure from share issuance. The company's debt-to-equity ratio of 0.32 is relatively low, but the negative net income and cash flow raise concerns about long-term credit risk. No recent events, filings, or transcripts are provided in the input data to inform the company's strategic direction or operational developments.